Showing results (1551-1560 of 1,715) with videos related to
Sort By:
Pageof 172
The Journal of Pediatrics|December 3, 2020
Considerations to Support Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures in Ambulatory ClinicsElizabeth D Cox, Sarah K Dobrozsi, Christopher B Forrest, et al.Journal of the Neurological Sciences|August 28, 2022
Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic strokeS T Lim, S J X Murphy, S M Murphy, et al.Advances in Neurology|October 9, 1999
Studies of the lethargic (lh/lh) mouse model of absence seizures: regulatory mechanisms and identification of the lh geneD A Hosford, F H Lin, Y Wang, et al.International Journal of Radiation Oncology, Biology, Physics|March 6, 2004
Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancerHasan Murshed, H Helen Liu, Zhongxing Liao, et al.International Journal of Radiation Oncology, Biology, Physics|August 12, 2003
Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancerStephen G Swisher, Jaffer A Ajani, Ritsuko Komaki, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphomaJohn F Seymour, Barbara Pro, Lillian M Fuller, et al.Antimicrobial Agents and Chemotherapy|May 8, 2019
Nucleoside Analogs with Selective Antiviral Activity against Dengue Fever and Japanese Encephalitis VirusesKeivan Zandi, Leda Bassit, Franck Amblard, et al.Journal of the National Cancer Institute|January 15, 1997
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610D J Grignon, R Caplan, F H Sarkar, et al.Cancer Research|August 9, 2003
The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cellsE Gabriella Barbacci, Leslie R Pustilnik, Ann Marie K Rossi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastasesIvan Milas, Ritsuko Komaki, Tsutomu Hachiya, et al.Pageof 172